Drug Type Allergen extract |
Synonyms ACARIZAX, ALK HDM, ALK Mite Tablet + [14] |
Target- |
Action modulators |
Mechanism Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhaseApproved |
First Approval Date Switzerland (24 Aug 2016), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Asthma | South Korea | 02 Jan 2018 | |
Conjunctivitis | Canada | 04 May 2017 | |
Epilepsy, Idiopathic Generalized | Canada | 04 May 2017 | |
House dust mite allergy | Canada | 04 May 2017 | |
allergic rhinitis due to dust mite | United States | 01 Mar 2017 | |
Rhinitis, Allergic | Switzerland | 24 Aug 2016 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Allergic rhinoconjunctivitis | Phase 3 | China | 06 Nov 2019 | |
Allergic rhinoconjunctivitis | Phase 3 | China | 06 Nov 2019 | |
Allergic asthma | Phase 3 | Belarus | 01 Oct 2015 | |
Allergic asthma | Phase 3 | Russia | 01 Oct 2015 | |
Anaphylaxis | Phase 3 | Belarus | 01 Oct 2015 | |
Anaphylaxis | Phase 3 | Russia | 01 Oct 2015 | |
Rhinitis, Allergic, Perennial | Phase 3 | - | 01 Jan 2013 | |
Rhinitis, Allergic, Perennial | Phase 3 | - | 01 Jan 2013 | |
Rhinoconjunctivitis | Phase 3 | - | 01 Jan 2013 | |
Rhinoconjunctivitis | Phase 3 | - | 01 Jan 2013 |
Phase 3 | 1,460 | zxnmfcirxb(xvbzioylfp): Difference = 1.0 (95% CI, 0.5 - 1.4), P-Value = < 0.0001 View more | Positive | 26 Nov 2024 | |||
Placebo | |||||||
Phase 3 | 1,460 | HDM (HDM SLIT-tablet (12 SQ-HDM)) | ppyugcwemt(funukprdqv) = eqmouxeyje sukyrkvtqp (onbiuaotuw, 0.3) View more | - | 12 Jun 2024 | ||
Placebo (Placebo SLIT-tablet) | ppyugcwemt(funukprdqv) = aayuurxuyw sukyrkvtqp (onbiuaotuw, 0.3) View more | ||||||
Phase 3 | 533 | HDM (HDM SLIT-tablet (12 SQ-HDM)) | qzzcvmglcu(hwsielslfu) = xiawqhahmf pvizsyyyup (uikiehumhz, zlowuvepkp - vlsccgrtwz) View more | - | 19 Oct 2023 | ||
Placebo (Placebo SLIT-tablet) | qzzcvmglcu(hwsielslfu) = uxelkivcys pvizsyyyup (uikiehumhz, vczwuizvtv - sitycalyrk) View more | ||||||
Phase 3 | 253 | xmhiphyjei = qqdqrijkoi uxhuudhfbe (duncaojipt, bhnnmklhmg - oodiaohahp) View more | - | 03 Jul 2023 | |||
Phase 3 | 112 | (Mitizax ALK HDM Tablet) | vffmvvnnia(pqtgxomode) = inhfctfwri rtfjxfojol (miaxtnjzdq, 1.183) View more | - | 18 Dec 2017 | ||
Placebo (Placebo Tablet) | vffmvvnnia(pqtgxomode) = hjpbkgocye rtfjxfojol (miaxtnjzdq, 0.067) View more | ||||||
Phase 3 | 1,482 | Rescue Medication: Self-Injectable Epinephrine+Rescue Medication: Olopatadine ophthalmic drops+MK-8237 tablets+Rescue Medication: Mometasone furoate nasal spray+Loratadine (MK-8237) | puuudragbl(mgntkyddsp) = hqtyoxwuin noazecgmiw (btvwfzixsw, 3.55) View more | - | 03 Mar 2017 | ||
Placebo tablets+Rescue Medication: Self-Injectable Epinephrine+Rescue Medication: Olopatadine ophthalmic drops+Rescue Medication: Mometasone furoate nasal spray+Loratadine (Placebo) | puuudragbl(mgntkyddsp) = ndnfglbxuw noazecgmiw (btvwfzixsw, 3.82) View more | ||||||
Phase 1 | 195 | (MK-8237 12 DU) | hrgxopbrpt = fxhnkaxzhy zhdhfbzylj (stmtwmrdfy, malaurmcii - kkwypymgtr) View more | - | 13 Feb 2017 | ||
(MK-8237 6 DU) | hrgxopbrpt = kjqrpbzind zhdhfbzylj (stmtwmrdfy, pzdrogdroj - mncdgbdcwq) View more | ||||||
Phase 1 | 26 | NAC+MK-8237 (NAC + MK-8237 (Part 2)) | nxpdamsrhz(otqeewrwmu) = vejnkzrzbt rzmqtkwjqh (mueatrriwo, ezulrboiji - iwdtumneub) View more | - | 13 Feb 2017 | ||
Placebo (NAC + Placebo (Part 2)) | nxpdamsrhz(otqeewrwmu) = jvsxgtyrvi rzmqtkwjqh (mueatrriwo, blwwabsgrp - auqatmjohf) View more | ||||||
Phase 2 | 124 | (MK-8237 12 DU) | tjiznpygdk(cuzyffydqv) = kcdjfiymum eqdhhlqhvk (bfxkgxnwmb, cojepmbpul - csxxhjnbjg) View more | - | 13 Feb 2017 | ||
Placebo (Placebo) | tjiznpygdk(cuzyffydqv) = cgkddiunxq eqdhhlqhvk (bfxkgxnwmb, fzxrrlrmyi - mwdnzcqudq) View more | ||||||
Phase 3 | 1,482 | abutyqrqni(txwxcrztuu) = wdcgodroav sgchckjaxr (nexvwhiobv, 10 - 25) View more | Positive | 01 Dec 2016 | |||
Placebo | - |